Robert J. Hombach

Robert J. Hombach (board member) discloses dealings in 6 companies, chiefly Biomarin Pharmaceutical Inc, Embecta Corp. and Aptinyx Inc. We count 18 filings; the first trade dates from 25 May 2021 and the latest from 12 August 2026.

Every open-market trade on record is a purchase: 4 purchases worth €217k, and no sale. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 14 share grants. In 2026 alone, the filings show 2 purchases and no sales.

The median purchase comes to €11k. Clusters matter here: 1 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

On 13 August 2026 came the latest disclosure, an open-market purchase for €194k in Embecta Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.